| 摘要: |
| 目的通过检测胃癌组织中切除修复交叉互补基因1（ERCC1）、胸苷酸合成酶基因（TYMS）mRNA的表达水平，分析其对化疗效果及预后的指导意义。方法选取晚期胃癌患者60例，均给予氟尿嘧啶、亚叶酸钙联合奥沙利铂进行化疗。采用分支DNA-液相芯片技术定量检测胃癌组织ERCC1、TYMSmRNA表达水平，并将患者分为ERCC1和TYMS共同中低表达组、ERCC1中低表达及TYMS高表达组、ERCC1高表达及TYMS中低表达组。随访3年，观察并比较3组患者的化疗有效率及生存率。结果3组患者化疗有效率分别为62.86%（22/35）、35.71%（5/14）、36.36%（4/11），差异无统计学意义（P＞0.05）；中位生存时间分别为20、10、10.5个月，1年生存率分别为65.71%、38.46%、40.00%，2年生存率分别为37.14%、0.00%、10.00%，3年生存率分别为14.29%、0.00%、0.00%，ERCC1和TYMS共同中低表达组患者1、2、3年生存率均高于另外两组（均P＜0.05）。结论晚期胃癌患者应用氟尿嘧啶、亚叶酸钙、奥沙利铂联合化疗，ERCC1和TYMS共同中低表达的患者生存率优于仅其中1个基因高表达的患者，而化疗效果差异尚不明显。 |
| 关键词: 胃癌 液相芯片技术 化疗 ERCC1 TYMS |
| DOI：10.12056/j.issn.1006-2785.2017.39.24.2017-2720 |
| 分类号: |
| 基金项目: |
|
| Association of ERCC1 and TYMS expression with efficacy of adjuvant chemotherapy and prognosis in patients with advanced gastric cancer |
|
|
|
Jinhua wenrong Hosptial
|
| Abstract: |
| Objective To investigate the association of expression level of ERCC1 and TYMS mRNA with the efficacy of
adjuvant chemotherapy and the prognosis in patients with advanced gastric cancer. Methods Sixty patients with advanced gastric cancer were treated with fluorouracil and leucovorin combined with oxaliplatin-based chemotherapy. The expressions of excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TYMS) genes in gastric cancer tissue were detected by branch DNA-liquid phase chip technique. According to the gene expression levels, the patients were grouped as moderate/low expression of both ERCC1 and TYMS (group 1), moderate/low expression of ERCC1 and high expression of TYMS (group 2), high expression of ERCC1 and moderate/low expression of TYMS (group 3). After three years of follow-up, the efficacy
of chemotherapy and the survival of patients were observed and compared among 3 groups. Results The response rates to chemotherapy in group 1, group 2 and group 3 were 62.86% (22/35), 35.71% (5/14) and 36.36% (4/11) (P ＞0.05).The median survival time of 3 groups was 20, 10 and 10.5 months, 1-year survival rates were 65.71%, 38.46% and 40.00%, 2-year survival
rates were 37.14%, 0.00% and 10.00%, 3-year survival rates were 14.29%, 0.00% and 0.00%, respectively. Compared with other two groups, the 1-, 2- and 3-year survival rates of patients with group 1 were significantly higher than those of other two groups (all P＜0.05). Conclusion Moderate or low expression of ERCC1 and TYMS is associated with higher survival rate in advanced gastric cancer patients with adjuvant chemotherapy, but not associated with the chemotherapy efficacy. |
| Key words: Gastric cancer Liquid chip technology Chemotherapy ERCC1 TYMS |
